Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Accumulated Expenses (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Accumulated Expenses for 8 consecutive years, with $16.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 14.38% year-over-year to $16.7 million, compared with a TTM value of $16.7 million through Sep 2025, down 14.38%, and an annual FY2024 reading of $23.0 million, up 79.5% over the prior year.
  • Accumulated Expenses was $16.7 million for Q3 2025 at X4 Pharmaceuticals, up from $13.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $23.0 million in Q4 2024 and bottomed at $6.9 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $13.0 million, with a median of $12.6 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses skyrocketed 85.03% in 2021, then tumbled 35.76% in 2022.
  • Year by year, Accumulated Expenses stood at $7.9 million in 2021, then soared by 52.91% to $12.0 million in 2022, then grew by 6.5% to $12.8 million in 2023, then skyrocketed by 79.5% to $23.0 million in 2024, then fell by 27.58% to $16.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for XFOR at $16.7 million in Q3 2025, $13.1 million in Q2 2025, and $12.6 million in Q1 2025.